Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1/2 3Phase 1 3Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 5Neoplasm Metastasis 2Carcinoma, Renal Cell 2Uveal Melanoma 1Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Motor Activity 1Lymphoid Interstitial Pneumonia 1Laryngeal Diseases 1Carcinoma, Merkel Cell 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 6Temozolomide 3Biopsy 3Bevacizumab 3posaconazole 2fluciclovine F-18 2Topotecan 2Specimen Handling 2Radiosurgery 2Pemetrexed 2Nivolumab 2Methotrexate 2Ketoconazole 2Fluorodeoxyglucose F18 2ribociclib 1relatlimab 1mycophenolic adenine dinucleotide 1montelukast 1gancotamab 1fluoromisonidazole 1fluorodopa F 18 1fludarabine phosphate 1etoposide phosphate 1eribulin 1dexamethasone acetate 1dexamethasone 21-phosphate 1clevudine 1ceritinib 1brivaracetam 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Brain Neoplasms × Ipilimumab × Clear all
NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
1 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡